Skip to main content

Adcirca FDA Approval History

FDA Approved: Yes (First approved May 22, 2009)
Brand name: Adcirca
Generic name: tadalafil
Dosage form: Tablets
Company: United Therapeutics Corporation
Treatment for: Pulmonary Arterial Hypertension

Adcirca (tadalafil) is a once-daily phosphodiesterase type 5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension (PAH).

Development timeline for Adcirca

May 26, 2009Approval FDA Approves Adcirca (tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.